Skip to main content

News

EXPLORE THE LATEST NEWS AND PUBLICATIONS FROM 3T BIOSCIENCES

January 4, 2024

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

October 25, 2023

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

January 9, 2023

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

October 25, 2022

3T Biosciences Announces Appointment of John Leonard, M.D. to its Board of Directors

Spiral cells graphic